NasdaqGS:NBIXBiotechs
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data In Older Tardive Dyskinesia Patients
Clinical data spotlight at PALTC26
Neurocrine Biosciences (NBIX) used the PALTC26 conference in Anaheim to spotlight new guidance and data on tardive dyskinesia care in older adults, centering on its INGREZZA treatment and real world patient reported outcomes.
See our latest analysis for Neurocrine Biosciences.
At a share price of US$131.60, Neurocrine Biosciences has seen a 1 year total shareholder return of about 28%, even as its 90 day share price return of roughly 6% suggests some...